3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Melanoma
25
Neoplasms
8
Neoplasm Metastasis
8
Colorectal Neoplasms
5
Lymphoma, Non-Hodgkin
4
Leukemia, Hairy Cell
4
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
3
Wilms Tumor
2
Thyroid Neoplasms
2
Thyroid Cancer, Papillary
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Xanthogranuloma, Juvenile
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Skin Neoplasms
1
Sarcoma, Clear Cell
1
Relapsed Pediatric Solid Tumor
1
Rare Tumour
1
Interventions
Cyclophosphamide
41
fludarabine
35
Tacrolimus
28
Mycophenolic Acid
27
Whole-Body Irradiation
25
Busulfan
24
fludarabine phosphate
21
Melphalan
19
thymoglobulin
16
Antilymphocyte Serum
16
Methotrexate
13
Thiotepa
12
Stem Cell Transplantation
9
Rituximab
9
Granulocyte Colony-Stimulating Factor
9
Filgrastim
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Nivolumab
5
ruxolitinib
4
merphos
4
Peripheral Blood Stem Cell Transplantation
4
Cytarabine
4
Cord Blood Stem Cell Transplantation
4
Bendamustine Hydrochloride
4
tocilizumab
3
itacitinib
3
fedratinib
3
dabrafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hematologic Neoplasms
×
Vemurafenib
×
Clear all
NCT05159245
2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2
Recruiting
250 enrolled